Skip to main content
Erschienen in: Journal of Cancer Research and Clinical Oncology 10/2017

20.06.2017 | Original Article – Clinical Oncology

Safety and efficacy of chemosaturation in patients with primary and secondary liver tumors

verfasst von: Martha M. Kirstein, Steffen Marquardt, Nils Jedicke, Silke Marhenke, Wolfgang Koppert, Michael P. Manns, Frank Wacker, Arndt Vogel

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 10/2017

Einloggen, um Zugang zu erhalten

Abstract

Background

Chemosaturation with percutaneous hepatic perfusion (CS-PHP; hepatic CHEMOSAT® delivery system; Delcath Systems Inc, USA) is a novel medical device, which delivers high doses of melphalan directly to the liver in patients with primary and secondary liver tumors while limiting systemic toxicity through hemofiltration of the hepatic venous blood. The aim of this study was to analyze the safety and efficacy of the second-generation CS-PHP after 54 treatments at Hannover Medical School, Germany.

Methods

Overall response rates (ORR) were assessed according to response evaluation criteria in solid tumors (RECIST1.1). Overall survival (OS), progression-free survival (PFS), and hepatic PFS (hPFS) were analyzed using the Kaplan–Meier estimation.

Results

29 patients were treated with CS-PHP as last-line therapy up to five sessions. 19 patients had unresectable hepatic metastases from solid tumors [ocular melanoma (OM) n = 11; colorectal carcinoma n = 2; pancreatic adenocarcinoma n = 2; periampular carcinoma n = 2; breast and endometrial cancer each n = 1] and 10 patients were diagnosed with hepatocellular or cholangiocarcinoma (HCC/CCA). ORR was 19.2%. Patients with OM had the highest ORR (33.3%). Similar to patients with OM, patients with hepatobiliary tumors had durable disease stabilization (40%). Median OS, PFS, and hPFS were 261, 117, and 135 days, respectively. Tumor volume negatively correlated with OS. Complications and toxicities included thrombocytopenia, cardiovascular events, ulcerous bleeding, and edema.

Conclusion

Second-generation CS-PHP seems to be effective and tolerable. Patient selection based on tumor volume and entity is of importance. Particularly, patients with OM and hepatobiliary tumors represent promising candidates for CS-PHP.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
Zurück zum Zitat Alexander HR Jr, Libutti SK, Pingpank JF, Bartlett DL, Helsabeck C, Beresneva T (2005) Isolated hepatic perfusion for the treatment of patients with colorectal cancer liver metastases after irinotecan-based therapy. Ann Surg Oncol 12:138–144CrossRefPubMed Alexander HR Jr, Libutti SK, Pingpank JF, Bartlett DL, Helsabeck C, Beresneva T (2005) Isolated hepatic perfusion for the treatment of patients with colorectal cancer liver metastases after irinotecan-based therapy. Ann Surg Oncol 12:138–144CrossRefPubMed
Zurück zum Zitat Alexander HR Jr, Bartlett DL, Libutti SK, Pingpank JF, Fraker DL, Royal R, Steinberg SM et al (2009) Analysis of factors associated with outcome in patients undergoing isolated hepatic perfusion for unresectable liver metastases from colorectal center. Ann Surg Oncol 16:1852–1859CrossRefPubMed Alexander HR Jr, Bartlett DL, Libutti SK, Pingpank JF, Fraker DL, Royal R, Steinberg SM et al (2009) Analysis of factors associated with outcome in patients undergoing isolated hepatic perfusion for unresectable liver metastases from colorectal center. Ann Surg Oncol 16:1852–1859CrossRefPubMed
Zurück zum Zitat BacalbaSa N, Balescu I, Dima S, Popescu I (2015) Long-term survivors after liver resection for breast cancer liver metastases. Anticancer Res 35:6913–6917PubMed BacalbaSa N, Balescu I, Dima S, Popescu I (2015) Long-term survivors after liver resection for breast cancer liver metastases. Anticancer Res 35:6913–6917PubMed
Zurück zum Zitat Braat MN, Samim M, van den Bosch MA, Lam MG (2016) The role of 90Y-radioembolization in downstaging primary and secondary hepatic malignancies: a systematic review. Clin Transl Imaging 4:283–295CrossRefPubMedPubMedCentral Braat MN, Samim M, van den Bosch MA, Lam MG (2016) The role of 90Y-radioembolization in downstaging primary and secondary hepatic malignancies: a systematic review. Clin Transl Imaging 4:283–295CrossRefPubMedPubMedCentral
Zurück zum Zitat de Ridder JA, Lemmens VE, Overbeek LI, Nagtegaal ID, de Wilt JH, Dutch Liver Surgery G (2016) Liver resection for metastatic disease; a population-based analysis of trends. Dig Surg 33:104–113CrossRefPubMed de Ridder JA, Lemmens VE, Overbeek LI, Nagtegaal ID, de Wilt JH, Dutch Liver Surgery G (2016) Liver resection for metastatic disease; a population-based analysis of trends. Dig Surg 33:104–113CrossRefPubMed
Zurück zum Zitat Egan KM, Seddon JM, Glynn RJ, Gragoudas ES, Albert DM (1988) Epidemiologic aspects of uveal melanoma. Surv Ophthalmol 32:239–251CrossRefPubMed Egan KM, Seddon JM, Glynn RJ, Gragoudas ES, Albert DM (1988) Epidemiologic aspects of uveal melanoma. Surv Ophthalmol 32:239–251CrossRefPubMed
Zurück zum Zitat Feldman ED, Pingpank JF, Alexander HR Jr (2004a) Regional treatment options for patients with ocular melanoma metastatic to the liver. Ann Surg Oncol 11:290–297CrossRefPubMed Feldman ED, Pingpank JF, Alexander HR Jr (2004a) Regional treatment options for patients with ocular melanoma metastatic to the liver. Ann Surg Oncol 11:290–297CrossRefPubMed
Zurück zum Zitat Feldman ED, Wu PC, Beresneva T, Helsabeck C, Rodriguez M, Bartlett DL, Libutti SK et al (2004b) Treatment of patients with unresectable primary hepatic malignancies using hyperthermic isolated hepatic perfusion. J Gastrointest Surg 8:200–207CrossRefPubMed Feldman ED, Wu PC, Beresneva T, Helsabeck C, Rodriguez M, Bartlett DL, Libutti SK et al (2004b) Treatment of patients with unresectable primary hepatic malignancies using hyperthermic isolated hepatic perfusion. J Gastrointest Surg 8:200–207CrossRefPubMed
Zurück zum Zitat Grover AC, Libutti SK, Pingpank JF, Helsabeck C, Beresnev T, Alexander HR Jr (2004) Isolated hepatic perfusion for the treatment of patients with advanced liver metastases from pancreatic and gastrointestinal neuroendocrine neoplasms. Surgery 136:1176–1182CrossRefPubMed Grover AC, Libutti SK, Pingpank JF, Helsabeck C, Beresnev T, Alexander HR Jr (2004) Isolated hepatic perfusion for the treatment of patients with advanced liver metastases from pancreatic and gastrointestinal neuroendocrine neoplasms. Surgery 136:1176–1182CrossRefPubMed
Zurück zum Zitat Habib A, Desai K, Hickey R, Thornburg B, Lewandowski R, Salem R (2015) Transarterial approaches to primary and secondary hepatic malignancies. Nat Rev Clin Oncol 12:481–489CrossRefPubMed Habib A, Desai K, Hickey R, Thornburg B, Lewandowski R, Salem R (2015) Transarterial approaches to primary and secondary hepatic malignancies. Nat Rev Clin Oncol 12:481–489CrossRefPubMed
Zurück zum Zitat Hughes MS, Zager J, Faries M, Alexander HR, Royal RE, Wood B, Choi J et al (2016) Results of a randomized controlled multicenter phase III trial of percutaneous hepatic perfusion compared with best available care for patients with melanoma liver metastases. Ann Surg Oncol 23:1309–1319CrossRefPubMed Hughes MS, Zager J, Faries M, Alexander HR, Royal RE, Wood B, Choi J et al (2016) Results of a randomized controlled multicenter phase III trial of percutaneous hepatic perfusion compared with best available care for patients with melanoma liver metastases. Ann Surg Oncol 23:1309–1319CrossRefPubMed
Zurück zum Zitat Jovanovic P, Mihajlovic M, Djordjevic-Jocic J, Vlajkovic S, Cekic S, Stefanovic V (2013) Ocular melanoma: an overview of the current status. Int J Clin Exp Pathol 6:1230–1244PubMedPubMedCentral Jovanovic P, Mihajlovic M, Djordjevic-Jocic J, Vlajkovic S, Cekic S, Stefanovic V (2013) Ocular melanoma: an overview of the current status. Int J Clin Exp Pathol 6:1230–1244PubMedPubMedCentral
Zurück zum Zitat Kirstein MM, Schweitzer N, Ay N, Boeck C, Lappas K, Hinrichs JB, Voigtlander T et al (2017a) Experience from a real-life cohort: outcome of 606 patients with hepatocellular carcinoma following transarterial chemoembolization. Scand J Gastroenterol 52(1):116–124CrossRefPubMed Kirstein MM, Schweitzer N, Ay N, Boeck C, Lappas K, Hinrichs JB, Voigtlander T et al (2017a) Experience from a real-life cohort: outcome of 606 patients with hepatocellular carcinoma following transarterial chemoembolization. Scand J Gastroenterol 52(1):116–124CrossRefPubMed
Zurück zum Zitat Kirstein MM, Schweitzer N, Winter T, Lappas K, Graen N, Kunstmann I, Voigtlander T et al (2017b) Patterns and challenges of treatment sequencing in patients with hepatocellular carcinoma -experience from a referral center. J Gastroenterol Hepatol. doi:10.1111/jgh.13761 PubMed Kirstein MM, Schweitzer N, Winter T, Lappas K, Graen N, Kunstmann I, Voigtlander T et al (2017b) Patterns and challenges of treatment sequencing in patients with hepatocellular carcinoma -experience from a referral center. J Gastroenterol Hepatol. doi:10.​1111/​jgh.​13761 PubMed
Zurück zum Zitat Lamarca A, Hubner RA, David Ryder W, Valle JW (2014) Second-line chemotherapy in advanced biliary cancer: a systematic review. Ann Oncol 25:2328–2338CrossRefPubMed Lamarca A, Hubner RA, David Ryder W, Valle JW (2014) Second-line chemotherapy in advanced biliary cancer: a systematic review. Ann Oncol 25:2328–2338CrossRefPubMed
Zurück zum Zitat Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC et al (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378–390CrossRefPubMed Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC et al (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378–390CrossRefPubMed
Zurück zum Zitat Moeslein FM, McAndrew EG, Appling WM, Hryniewich NE, Jarvis KD, Markos SM, Sheets TP et al (2014) Evaluation of Delcath Systems’ Generation 2 (GEN 2) melphalan hemofiltration system in a porcine model of percutaneous hepatic perfusion. Cardiovasc Intervent Radiol 37:763–769CrossRefPubMedPubMedCentral Moeslein FM, McAndrew EG, Appling WM, Hryniewich NE, Jarvis KD, Markos SM, Sheets TP et al (2014) Evaluation of Delcath Systems’ Generation 2 (GEN 2) melphalan hemofiltration system in a porcine model of percutaneous hepatic perfusion. Cardiovasc Intervent Radiol 37:763–769CrossRefPubMedPubMedCentral
Zurück zum Zitat Norstein J, Silen W (1997) Natural history of liver metastases from colorectal carcinoma. J Gastrointest Surg 1:398–407CrossRefPubMed Norstein J, Silen W (1997) Natural history of liver metastases from colorectal carcinoma. J Gastrointest Surg 1:398–407CrossRefPubMed
Zurück zum Zitat Pearson AS, Izzo F, Fleming RY, Ellis LM, Delrio P, Roh MS, Granchi J et al (1999) Intraoperative radiofrequency ablation or cryoablation for hepatic malignancies. Am J Surg 178:592–599CrossRefPubMed Pearson AS, Izzo F, Fleming RY, Ellis LM, Delrio P, Roh MS, Granchi J et al (1999) Intraoperative radiofrequency ablation or cryoablation for hepatic malignancies. Am J Surg 178:592–599CrossRefPubMed
Zurück zum Zitat Peixoto RD, Speers C, McGahan CE, Renouf DJ, Schaeffer DF, Kennecke HF (2015) Prognostic factors and sites of metastasis in unresectable locally advanced pancreatic cancer. Cancer Med 4:1171–1177CrossRefPubMedPubMedCentral Peixoto RD, Speers C, McGahan CE, Renouf DJ, Schaeffer DF, Kennecke HF (2015) Prognostic factors and sites of metastasis in unresectable locally advanced pancreatic cancer. Cancer Med 4:1171–1177CrossRefPubMedPubMedCentral
Zurück zum Zitat Pingpank JF, Libutti SK, Chang R, Wood BJ, Neeman Z, Kam AW, Figg WD et al (2005) Phase I study of hepatic arterial melphalan infusion and hepatic venous hemofiltration using percutaneously placed catheters in patients with unresectable hepatic malignancies. J Clin Oncol 23:3465–3474CrossRefPubMedPubMedCentral Pingpank JF, Libutti SK, Chang R, Wood BJ, Neeman Z, Kam AW, Figg WD et al (2005) Phase I study of hepatic arterial melphalan infusion and hepatic venous hemofiltration using percutaneously placed catheters in patients with unresectable hepatic malignancies. J Clin Oncol 23:3465–3474CrossRefPubMedPubMedCentral
Zurück zum Zitat Valle JW, Furuse J, Jitlal M, Beare S, Mizuno N, Wasan H, Bridgewater J et al (2014) Cisplatin and gemcitabine for advanced biliary tract cancer: a meta-analysis of two randomised trials. Ann Oncol 25:391–398CrossRefPubMed Valle JW, Furuse J, Jitlal M, Beare S, Mizuno N, Wasan H, Bridgewater J et al (2014) Cisplatin and gemcitabine for advanced biliary tract cancer: a meta-analysis of two randomised trials. Ann Oncol 25:391–398CrossRefPubMed
Zurück zum Zitat van Iersel LB, Gelderblom H, Vahrmeijer AL, van Persijn van Meerten EL, Tijl FG, Putter H, Hartgrink HH et al (2008) Isolated hepatic melphalan perfusion of colorectal liver metastases: outcome and prognostic factors in 154 patients. Ann Oncol 19:1127–1134CrossRefPubMed van Iersel LB, Gelderblom H, Vahrmeijer AL, van Persijn van Meerten EL, Tijl FG, Putter H, Hartgrink HH et al (2008) Isolated hepatic melphalan perfusion of colorectal liver metastases: outcome and prognostic factors in 154 patients. Ann Oncol 19:1127–1134CrossRefPubMed
Zurück zum Zitat Vogl TJ, Zangos S, Scholtz JE, Schmitt F, Paetzold S, Trojan J, Orsi F et al (2014) Chemosaturation with percutaneous hepatic perfusions of melphalan for hepatic metastases: experience from two European centers. Rofo 186:937–944CrossRefPubMed Vogl TJ, Zangos S, Scholtz JE, Schmitt F, Paetzold S, Trojan J, Orsi F et al (2014) Chemosaturation with percutaneous hepatic perfusions of melphalan for hepatic metastases: experience from two European centers. Rofo 186:937–944CrossRefPubMed
Zurück zum Zitat Ye T, Yang B, Tong H, Zhang Y, Xia J (2015) Long-term outcomes of surgical resection for liver metastasis from breast cancer. Hepatogastroenterology 62:688–692PubMed Ye T, Yang B, Tong H, Zhang Y, Xia J (2015) Long-term outcomes of surgical resection for liver metastasis from breast cancer. Hepatogastroenterology 62:688–692PubMed
Metadaten
Titel
Safety and efficacy of chemosaturation in patients with primary and secondary liver tumors
verfasst von
Martha M. Kirstein
Steffen Marquardt
Nils Jedicke
Silke Marhenke
Wolfgang Koppert
Michael P. Manns
Frank Wacker
Arndt Vogel
Publikationsdatum
20.06.2017
Verlag
Springer Berlin Heidelberg
Erschienen in
Journal of Cancer Research and Clinical Oncology / Ausgabe 10/2017
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-017-2461-z

Weitere Artikel der Ausgabe 10/2017

Journal of Cancer Research and Clinical Oncology 10/2017 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.